Semaglutide vs Tirzepatide: GLP-1 vs Dual Agonist Compared
Semaglutide (Wegovy/Ozempic) is a GLP-1 agonist delivering ~15.8% weight loss, while tirzepatide (Zepbound/Mounjaro) is a dual GIP/GLP-1 agonist achieving up to 22.5% loss in SURPASS/SURMOUNT trials.
Overview
Semaglutide and tirzepatide are the two leading injectable incretin therapies for obesity and type 2 diabetes. Semaglutide (Wegovy, Ozempic) is a pure GLP-1 receptor agonist, while tirzepatide (Zepbound, Mounjaro) is the first dual GIP/GLP-1 receptor agonist, simultaneously activating both major incretin pathways. Both are dosed weekly, but tirzepatide's dual mechanism translates to materially greater weight loss and glycemic improvement.
Quick Comparison
| Feature | Semaglutide | Tirzepatide |
|---------|-------------|-------------|
| Brand names | Wegovy, Ozempic | Zepbound, Mounjaro |
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Receptor targets | 1 (GLP-1) | 2 (GIP + GLP-1) |
| Dosing frequency | Weekly (subcutaneous) | Weekly (subcutaneous) |
| Max weight loss | 14.9-15.8% | Up to 22.5% |
| HbA1c reduction | ~1.6-1.8% | ~2.0-2.4% |
| FDA approval (weight) | 2021 | 2023 |
| Oral form | Yes (Rybelsus/oral Wegovy) | No |
| Cardiovascular outcome | SELECT: 20% MACE reduction | CVOT ongoing |
Mechanism: GLP-1 vs Dual Agonist
Semaglutide exclusively targets the GLP-1 receptor, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Tirzepatide activates both GLP-1 and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) adds complementary effects: additional insulin secretion, improved adipose tissue metabolism, and reduced nausea. The dual mechanism is why tirzepatide achieves greater weight loss than any GLP-1-only agent.
Efficacy: STEP Trials vs SURPASS/SURMOUNT
- **Semaglutide (STEP program):** STEP 1 showed 14.9% loss at 68 weeks; STEP 5 confirmed durability at 2 years (15.2%). The SELECT cardiovascular trial showed a 20% reduction in major adverse cardiovascular events (MACE) in patients with pre-existing cardiovascular disease.
- **Tirzepatide (SURPASS for diabetes, SURMOUNT for obesity):** SURMOUNT-1 showed up to 22.5% weight loss at 72 weeks at the 15 mg dose, with 91% of patients achieving at least 5% loss. SURMOUNT-4 demonstrated sustained 26% loss over 88 weeks including a taper phase. In SURPASS-2 (head-to-head vs semaglutide for diabetes), tirzepatide reduced HbA1c by 2.0-2.4% vs semaglutide's 1.6%.
Dosing Schedules
- **Semaglutide (Wegovy):** 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, titrating every 4 weeks.
- **Tirzepatide (Zepbound):** 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly, titrating every 4 weeks. The 5 mg dose typically achieves 15% loss; higher doses incrementally improve.
Both require slow titration to manage GI side effects.
Side Effect Profiles
Both agents produce primarily gastrointestinal effects: nausea, diarrhea, vomiting, constipation, and abdominal pain, peaking during dose escalation. Tirzepatide's GIP component may partially buffer GLP-1-mediated nausea, and discontinuation rates in trials were comparable. Rare risks for both include pancreatitis, gallbladder disease, and acute kidney injury (largely from dehydration during vomiting). Both carry boxed warnings for thyroid C-cell tumors based on rodent data and are contraindicated in pregnancy and MEN2/MTC history.
Cost & Availability
Both are brand-only in the U.S. with similar list prices (~$1,000-1,200/month). Tirzepatide has faced fewer supply constraints than semaglutide. Access varies widely by insurance; Medicare now covers anti-obesity medications under the 2025 CMS expansion.
Which Should You Choose?
**For maximum weight loss:** Tirzepatide — up to 22.5% vs 15.8%.
**For established cardiovascular benefit:** Semaglutide (SELECT data). Tirzepatide's CVOT (SURPASS-CVOT) results pending.
**For oral administration:** Semaglutide (Rybelsus/oral Wegovy).
**For diabetes with need for maximal HbA1c reduction:** Tirzepatide (2.0-2.4% vs 1.6-1.8%).
**For ease of access:** Varies regionally; check local insurance coverage and supply.
Both therapies should be paired with lifestyle counseling and clinician oversight for titration and adverse-effect management.
Related Peptides
Frequently Asked Questions
Is tirzepatide more effective than semaglutide for weight loss?
Yes. SURMOUNT-1 showed up to 22.5% weight loss with tirzepatide vs 14.9-15.8% with semaglutide in STEP trials — about 40-50% more weight loss.
What makes tirzepatide a 'dual agonist'?
Tirzepatide activates both GIP and GLP-1 receptors, whereas semaglutide targets only GLP-1. The GIP component adds complementary metabolic effects that improve weight loss and may reduce nausea.
Which drug has proven cardiovascular benefits?
Semaglutide — the SELECT trial showed a 20% reduction in major adverse cardiovascular events. Tirzepatide's cardiovascular outcome trial is still ongoing.
Can I take either drug orally?
Only semaglutide has an oral formulation (Rybelsus for diabetes, oral Wegovy for weight loss since 2026). Tirzepatide is injectable only.
Are the side effects different?
Both have similar GI side effects (nausea, vomiting, diarrhea). Tirzepatide's GIP activity may slightly buffer GLP-1-mediated nausea, but discontinuation rates are broadly comparable.
References
- Jastreboff AM, et al. SURMOUNT-1: Tirzepatide Once Weekly for Obesity. N Engl J Med 2022;387:205-216.
- Garvey WT, et al. SURMOUNT-4: Tirzepatide for Weight Maintenance. JAMA 2023;329:1374-1385.
- Wilding JPH, et al. STEP 1: Semaglutide in Adults with Obesity. N Engl J Med 2021;384:989-1002.
- FDA Prescribing Information: Zepbound (tirzepatide) and Wegovy (semaglutide).